News | December 06, 2023
Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
WINLEVI works differently from any other topical acne treatment
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
Subscribe To Our Newsletter & Stay Updated
